Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02658981
Title Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UAB Comprehensive Cancer Center Birmingham Alabama 35294-3410 United States Details
Jonsson Comprehensive Cancer Center at UCLA Los Angeles California 90095 United States Details
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 United States Details
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Henry Ford Hospital Detroit Michigan 48202 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10021 United States Details
Wake Forest University Comprehensive Cancer Center Winston-Salem North Carolina 27157-1096 United States Details
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195 United States Details
Abrams Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
Hillman Cancer Center at University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field